Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines ...

Pfizer has reached a turning point.

Pfizer (PFE)-backed Priovant Therapeutics wins U.S. FDA's priority review for skin disorder therapy with a targeted action ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

(RTTNews) - Pfizer Inc. (PFE) on Friday said the U.S. Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for HYMPAVZI.

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts ...

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...